Journal of the Neurological Sciences
Volume 233, Issues
Samuel J. JacksonCorresponding Author Contact Information, E-mail The Corresponding Author, Lara T. Diemel, Gareth Pryce and David Baker
Department of Neuroinflammation, Institute of Neurology, University College London, 1 Wakefield Street, London WC1N 1PJ, UK
Available online 13 May 2005.
The current failure of potent immunosuppressive agents to control progressive disease in multiple sclerosis has moved a focus from immunotherapy towards the need for neuroprotection. There is increasing evidence for cannabinoid-mediated control of symptoms, which is being more supported by the underlying biology. However there is accumulating evidence in vitro and in vivo to support the hypothesis that the cannabinoid system can limit the neurodegenerative possesses that drive progressive disease, and may provide a new avenue for disease control.
Keywords: CB1; Cannabinoid; Experimental allergic encephalomyelitis; Multiple Sclerosis